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Abstract
 .  .  .Incorporation of N- v-carboxy acylamido-phosphatidylethanolamines -PEs into large unilamellar vesicles LUVs of
 .L-a-distearoylphosphatidylcholine DSPC was found to dramatically increase the in vivo liposomal circulation lifetime in
rats, reaching a maximal effect at 10 mol.% of the total phospholipid. Neither pure DSPC liposomes nor those with the
 .longest circulating derivative, N-glutaryl-dipalmitoylphosphatidylethanolamine -DPPE , were found to significantly bind
complement from serum. Therefore, the relatively short circulation time of pure DSPC liposomes did not appear to be
related to greater complement opsonization leading to uptake by the reticuloendothelial system. However, N- v-
.carboxy acylamido-PEs were particularly efficient inhibitors of a limited aggregation detected for pure DSPC liposomes.
The aggregation tendency of DSPC liposomes incorporating various structural analogs of N-glutaryl-DPPE correlated
inversely with the circulation lifetimes. Therefore, it is concluded that such PE derivatives enhance the circulation time by
preventing liposomal aggregation and avoiding a poorly understood mechanism of clearance that is dependent on size but is
 .independent of complement opsonization. At high concentrations of N-glutaryl-DPPE above 10 mol.% , the liposomes
exhibited strong complement opsonization and were cleared from circulation rapidly, as were other highly negatively
charged liposomes. These data demonstrate that both the lack of opsonization and the lack of a tendency to aggregate are
 .required for long circulation. Liposomal disaggregation via N- v-carboxy acylamido-PEs yields a new class of large
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unilamellar DSPC liposomes with circulation lifetimes that are comparable to those of sterically stabilized liposomes.
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1. Introduction
The propensity of liposomal drug carriers to be
taken up by the phagocytic cells of the reticuloendo-
 .thelial system RES can affect many important phar-
maceutical properties, especially the in vivo circula-
tion lifetime. Designing long-circulating liposomes
w xhas been a major goal of liposome research 1–5 .
Complex interactions with plasma opsonins and
phagocytic cells can determine the ultimate in vivo
consequences for liposomes. In particular, C3 is a
crucial component in the serum complement cascade
that opsonizes particles and liposomes and plays a
w xmajor role in their clearance by the RES 6–9 .
Liposomal size, surface charge, surface hydrophilic-
ity and specific lipid composition can influence the
rate of RES uptake. For instance, liposomes that
contain cholesterol and a high surface charge density,
imparted by phospholipids such as phosphatidylglyc-
w xerol, are strong activators of C3 10 , leading to rapid
clearance by the RES.
A number of liposomal surface-modifying materi-
w xals, such as glycolipids 11–16 , or phospholipids
w xlinked to hydrophilic polymers 17–28 , have been
introduced to inhibit RES uptake. Prior to the inven-
tion of these additives, small unilamellar vesicles
 .SUVs containing rigid gel-phase phospholipids,
 .such as distearoylphosphatidylcholine DSPC , were
wconsidered the best long-circulating liposomes 29–
x36 . However, the small size requirement was not
always optimal for drug delivery.
The circulation lifetimes of some liposomal formu-
lations are also significantly enhanced by derivatives
 .of phosphatidylethanolamine PE , prepared by the
reaction of dicarboxylic acids with the free amine
 .group of PE to give N- v-carboxy acylamido-PEs
 . w xsee Fig. 1 37 . Therefore, it was of interest to
examine this relatively new mediator of enhanced
circulation time in terms of mechanism and efficacy.
This was tested in intermediate-to-large vesicles ;
.100 nm diameter composed of DSPC, which do not
exhibit the relatively long circulation time character-
istics of small sonicated vesicles. We report here on
Fig. 1. Chemical structures of phosphatidylethanolamine deriva-
tives.
the enhancement of circulation lifetimes of such lipo-
somes and an investigation of the role of complement
and effective particle size. Portions of this work were
w xpresented previously in abstract form 38 .
2. Materials and methods
2.1. Materials
Male Sprague Dawley rats were purchased from
 .Charles River Wilmington, MA, USA . DSPC was
purchased from Princeton Lipids Princeton, NJ,
.  .USA . PEG-DSPE 2000 MW and DSPG were ob-
tained from Avanti Polar Lipids Alabaster, AL,
. USA , while the cholesterol was from Sigma St.
. w3 xLouis, MO, USA . The H cholesteryl hexadecyl
ether was purchased from Dupont NEN Research
 . Products Boston, MA, USA . Ethanol dehydrated
.200 proof was obtained from Pharmco Products
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 .  .Bayonne, NJ, USA . A 0.9% wrv saline solution,
for injection, was from Abbott Laboratories North
.Chicago, IL, USA . Sodium barbital, dextrose, gelatin
 q2veronal buffer GVB : 141 mM NaCl, 0.15 mM
CaCl , 0.5 mM MgCl , 1.8 mM sodium barbital, 3.12 2
.mM barbituric acid, 0.1% gelatin, pH 7.3–7.4 , anti-
 .body sensitized sheep erythrocytes EA7S and
lyophilized rat serum were from Sigma. EDTA was
purchased from Boehringer Mannheim Biochemicals
 .Indianapolis, IN, USA .
2.2. Chemical synthesis of DPPE deri˝ati˝es
N-Glutaryl-, N-butyryl-, N-valeryl- and N-suc-
cinyl-DPPE were prepared by heating a suspension of
 .dipalmitoylphosphatidylethanolamine DPPE in an-
hydrous chloroform at 50–558C until a clear solution
was obtained. After cooling this solution to room
temperature, triethylamine and the appropriate anhy-
dride were added and the resulting solution was
stirred at room temperature. After 3 h, chloroform
was removed and the residue was chromatographed
on a silica gel column that was eluted with chloro-
 .form–methanol–water 65:25:4, vrvrv . The prod-
ucts were dried in a vacuum oven at 608C for 6 h to
give a white crystalline material, with an approximate
yield of 80%. N-Tartaryl-DPPE was prepared using
disuccinimidyl tartrate instead of the anhydride and it
was purified by passing the crude material through a
Sephadex LH-20 column in chloroform–methanol
 .1:1, vrv followed by silica gel column chromatog-
raphy in chloroform–methanol–water 65:25:4,
.vrvrv . After lyophilization, the final product was
obtained as a semi-solid material at a yield of 47%.
All of the compounds described above gave a single
 .spot on silica thin layer chromatography TLC
w  .65:25:6 vrv chloroform–methanol–water on
.Whatman K6 silica gel 60 A plates and were charac-
 . 1terized as being pure by infrared IR and H NMR
spectroscopy. In particular, the R values for N-f
glutaryl, succinyl, tartaryl, butyryl and valeryl deriva-
tives were 0.26, 0.25, 0.49, 0.44 and 0.46, respec-
tively. 1H NMR peaks from the methylenes a and b
to the original diacid carboxyl groups appeared be-
tween 2 and 3 ppm from tetramethylsilane, with the
correct ratio to the rest of the phospholipid protons.
For the monoacid derivatives, peaks a to the amide
linkage also appeared in the same range, with the
appropriate amplitude. For example, for N-glutaryl-
1  . DPPE: H NMR CDCl , 300 MHz d 5.3–5.1 1H,3
.  .  .m , 4.5–4.3 1H, 2d , 4.2–4.0 1H, m , 4.0–3.89
 .  .  .4H, m , 3.6–3.4 2H, t , 2.5–2.3 2H, m , 2.3–2.1
 .  .  .6H, m , 2.1–1.8 2H, m , 1.8–1.5 4H, m , 1.5–1.1
 .  .48H, m and 1.0–0.7 6H, m . Infrared spectra of the
N-glutaryl-DPPE product displayed the expected car-
boxylic carbonyl stretch at approximately 1700 cmy1.
2.3. Liposome preparation
 .Large unilamellar vesicles LUVs were prepared
from dry lipid films and extruded as described previ-
w xously 39 . Radiolabeled samples contained 5 mCirml
w3 xof H cholesteryl hexadecyl ether, a relatively non-
w xexchangeable probe 40,41 , in the final sample vol-
ume, giving a ratio of 1 to 4000 lipid molecules. The
lipid film was hydrated and extruded above the main
phase transition temperature of DSPC to a final lipid
concentration of 30 mM. Pyrogen-free saline for
 .injection 0.9%, wrv, NaCl was used as a buffer in
all animal studies. Samples for microscopy and tur-
bidity measurements also contained 10 mM HEPES.
The liposomal samples used in the in vitro comple-
w q2ment assays were suspended in buffer A GVB
 . xplus 0.1% wrv dextrose . The pH of samples con-
 .taining N- v-carboxy acylamido-PEs required ad-
justment with NaOH after hydration to bring the pH
 .to near seven except for the N-tartaryl derivative ,
due to dissociation of the carboxyl andror phosphate
protons.
 .Small unilamellar vesicles SUVs were prepared
by probe sonication at a temperature above the T ofm
the lipid, using a Branson 450 sonicator Danbury,
.CT .
 .DSPCrN-glutaryl-DPPE 9:1 interdigitation-fu-
 .sion vesicles IFVs were prepared in saline for injec-
tion from sonicated SUVs using 4 M ethanol, as
w xpreviously described 42 .
The phosphate content of the final LUV prepara-
tions was determined by the method of Chen et al.
w x43 . All liposome samples were stored at 48C
overnight before use.
2.4. Liposome sizing and turbidity measurements
The average diameter of each of the different LUV
formulations was determined by quasi-elastic light
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 .scattering QELS using a NICOMP 270 particle
sizer Particle Sizing Systems, Santa Barbara, CA,
. USA at 608C to ensure that the bilayer was in the
.liquid-crystalline phase and fit by a simple number-
weighted Gaussian size distribution. Surface area-
weighted average diameters were calculated from
number-weighted histograms, with the distribution
half-width defined as 2.354 times the standard devia-
tion. All liposomes, except those in the size depen-
dence studies, were extruded to a final surface area-
weighted diameter of 120 to 144 nm, with distribu-
tion widths at half height of approximately 35 nm.
One exception was the DSPCrcholrDSPGrPEG-
 .DSPE 1:4:4:1 formulation, which had an average
diameter of 69 nm.
The sizes of liposomes used in the size-depen-
dence experiments are shown in the caption to Fig. 5.
IFVs and the 200, 400, 600 and 800 nm pore size
LUVs were evaluated by freeze-fracture electron mi-
w xcroscopy, as described in Boni et al. 44 rather than
by QELS. Over 1000 liposomes were measured for
each size distribution histogram. The surface area-
weighted average diameter and the corresponding
standard deviation were calculated directly from the
size distribution histograms following standard equa-
w xtions for weighted averages 45 . The sizes obtained
by this method were very close to the number-
weighted sizes from QELS, except at the larger lipo-
some sizes, where the QELS method is very inaccu-
rate.
The aggregation levels of the LUV samples were
examined at concentrations and temperatures at which
the sample was injected into the rats, using phase
contrast microscopy and turbidity measurements with
short path-length cuvettes. Quantitative dynamic light
scattering methods are not applicable to heteroge-
neous aggregated samples. Therefore, phase contrast
and Nomarski photomicrographs of liposome samples
were taken at room temperature using either a 20=
objective or a 40= oil immersion objective with an
Olympus BH-2 microscope and an Olympus PM-
10ADS exposure control unit New YorkrNew Jer-
.sey Scientific, Middlebush, NJ, USA . The turbidity
measurements were made at approximately the same
lipid concentration as was used in the in vivo experi-
ments and at several dilutions of the sample concen-
 .tration. The optical density OD at 450 nm for each
LUV formulation was measured using either a 1 or
0.1 mm path-length quartz cuvette Hellma, Jamaica,
.NY, USA at room temperature in a UV-2101PC
spectrophotometer Shimadzu Scientific Instruments,
.Princeton, NJ, USA . Quantitative turbidity compar-
isons of different formulations were made by normal-
ization of the OD at 450 nm for sample lipid concen-
tration and cuvette path-length.
2.5. In ˝itro liposome-induced complement depletion
assay
These assays are based on the depletion of comple-
ment from serum by liposomes and its detection by
the relative ability of the treated serum to mediate
complement-dependent lysis of activated red blood
w xcells 46 . Liposome-induced complement activation
was measured in 1.5 ml eppendorf centrifuge tubes in
a two-step assay. First, 200 ml of liposomes were
incubated for 30 min at 378C with 100 ml of rat
 . serum that was diluted 1:1 vrv with buffer A see
.above . The final lipid concentrations at this step in
the assay ranged from 57 to 77 mM. Samples were
incubated in an Eppendorf 5436 Thermomixer
 .Brinkmann Instruments, Westbury, NY, USA with
gentle shaking. Then, 300 ml of buffer A were added,
the sample was vortex-mixed and centrifuged at 8000
=g for 4 min. A 100-ml volume of the supernatant
was removed and was two-fold serially diluted eight
times in buffer A. A 100-ml aliquot of antibody-
 . 8activated sheep red blood cells EA7S at 1P10
cellsrml was added to each tube. All the tubes were
then incubated for 30 min at 378C. The hemolysis
reaction was stopped by the addition of 300 ml of ice
cold buffer B 150 mM NaCl, 75 mM barbital, 0.1%
.gelatin and 20 mM EDTA, pH 7.5 . Unlysed red
blood cells were sedimented for 4 min at 8000=g.
Hemolysis was determined from the OD at 415 nm of
250 ml aliquots, using a microplate reader. The fi-
delity of the hemolysis assay was ascertained by the
smooth monotonic nature of the data and its repro-
ducibility. Furthermore, positive and negative con-
trols were used in each series of experiments to
correct for any differences in the hemoglobin re-
sponse from a given red cell preparation. In addition,
measurement of both the OD at 415 nm and the use
of Drabkin’s reagent gave a linear response to
hemoglobin in the range tested in the hemolysis
experiments. Liposome light-scattering and residual
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red cell hemolysis were corrected for using
liposome-only and red cell-only blanks.
Hemolysis data were plotted on a log scale in
terms of the serum dilution factor, which is frac-
tional, i.e. a 1:100 dilution of serum is equal to 0.01.
A shift of the curve to the right indicates that lipo-
somes have bound complement. An alternative
method of expressing the data is in terms of the
w xCH50 46 , the serum dilution at which 50% hemoly-
 .sis occurs. Hemolysis 50% at a 1:100 dilution level
w xwould give a CH50 of 100 46 . The CH50 values
used for Table 2 were calculated by a linear fit to a
w xlog–log version of the von Krogh equation 46 .
Percentage CH50 decreases were calculated relative
to the negative buffer control of the sample set. A
two sample t-test analysis, assuming equal variances
 .Microsoft Excel version 5.0 , was used to test for
statistical significance. Based on C3 concentrations in
human serum and extrapolating to rats, it can be
estimated that as few as three C3 molecules associ-
ated per liposome may cause total depletion of C3
under the conditions of these experiments.
2.6. Animal experiments
Male Sprague Dawley rats between 330 and 400
.g were weighed just prior to the experiment. Lipo-
some preparations were given by a single bolus injec-
tion in the lateral tail vein at 50 mgrkg. The injec-
w3 xtion volumes contained 4 to 5 mCi of H cholesteryl
hexadecyl ether per rat and were typically 0.8 to 1.0
ml. The pharmacokinetics of the DSPC and
DSPCrN-glutaryl-DPPE LUVs were essentially in-
dependent of lipid dose from 10 to 300 mgrkg
 .unpublished results . Whole-blood samples of 0.3 to
0.5 ml were withdrawn under CO anesthesia by2
retro-orbital bleeding from each rat. Blood was col-
lected in EDTA-containing microtainer tubes Becton
.Dickinson, Rutherford, NJ, USA using heparinized
microhematocrit capillary tubes Fisher Scientific,
.Pittsburgh, PA, USA . The blood plasma fractions
were obtained by sedimentation in a Hermle model
 .Z230 benchtop centrifuge Brinkmann Instruments .
The percentage of the total dose in the plasma at
 .each time point % dose was calculated as
 4 w x 4P rml = plasma volume rT =100 whereDPM DPM
P rml is the DPM per ml of plasma and T isDPM DPM
the total DPM injected into the rat. Plasma volume
w xwas taken to be 4.04 mlr100 g body weight 47 .
The circulation lifetimes of the different liposome
formulations were compared by integration of the %
dose in the plasma to give the ‘‘area under the
 .curve’’ AUC for each rat, determined by summing
the areas under trapezoidal segments between 0 and
24 h. The % dose at ts0 was set at 100%. In order
to make comparisons between different liposome for-
mulations easier, each of the average AUCs were
normalized to the AUC of the 200 nm pore size
 .DSPCrN-glutaryl-DPPE 9:1 LUVs. The average
and standard deviation of the normalized AUC was
calculated for each formulation. A two sample t-test
analysis, assuming equal variances Microsoft Excel
.version 5.0 , was used to test for statistical signifi-
cance. When the fraction of liposomal material recov-
 .ered in plasma taking whole blood as 100% was
used to correct plasma AUC values for each liposome
composition, the differences between corrected and
original values were within the error of the measure-
ments.
3. Results
3.1. N-glutaryl-DPPE enhancement of circulation
lifetime
It was of interest initially to determine whether
 .N- v-carboxy acylamido-PEs could indeed enhance
the circulation lifetimes of approximately 100 nm
 .diameter DSPC liposomes LUVs . Liposomes with
various percentages of N-glutaryl-DPPE were com-
 .pared to pure DSPC liposomes Fig. 2 . The plasma
clearance of 100 nm DSPC LUVs was apparently
biphasic, consisting of an initial phase with t of1r2
less than 5 min followed by a much slower phase. It
is clear that a dramatic increase in lifetime is afforded
by incorporation of only 10 mol.% of the N-glutaryl
derivative, primarily decreasing the very rapid clear-
ance. The enhanced circulation lifetime was observed
up to 10 mol.%, but at higher concentrations, the
circulation time decreased, a phenomenon discussed
below.
Large hydrophilic polyethylene glycol groups co-
valently linked to phospholipid headgroups are known
to sterically stabilize certain liposomes, preventing
complement fixation and RES uptake and leading to
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Fig. 2. Dependence of the in vivo circulation lifetime of
DSPCrN-glutaryl-DPPE LUVs on the membrane concentration
of N-glutaryl-DPPE. The liposomes were radiolabeled with
w3 xH cholesteryl hexadecyl ether. Male Sprague Dawley rats were
dosed at 50 mgrkg with a bolus tail vein injection. Typical time
courses of percentage of original dose remaining in plasma were
measured as described in Section 2. The percentage of total lipid
dose still present in the plasma as a function of time after
 .  .  .  .injection is shown for 0 -B- , 5 -v- , 10 -’- , 20 -l- and
 .40 --- mol.% N-glutaryl-DPPE in DSPC. The areas under the
 .curves AUCs were calculated from such circulation lifetime
profiles as described in Section 2. The AUC "standard devia-
.tion as a function of composition is shown in the inset. Between
four and twelve experiments were averaged for each data point.
 .long circulation lifetimes see Section 1 . The circula-
 .tion lifetime profile of DSPCrN-glutaryl-DPPE 9:1
LUVs are compared to the profiles of identically
prepared D S P C r po lyethy lene g lyco l-d i -
 .stearoylphosphatidylethanolamine PEG-DSPE and
pure DSPC liposomes in Fig. 3. The circulation
lifetimes of the N-glutaryl-DPPE-containing lipo-
Fig. 3. In vivo circulation lifetime of different DSPC LUV
formulations. The percentage of total lipid dose still present in
the plasma as a function of time after injection is shown for the
 .following LUV formulations: DSPCrN-glutaryl-DPPE 9:1 -B-,
 .DSPC -v- and DSPCrPEG-DSPE 9:1 -’-. Plasma clearance
profiles for DSPC LUVs represent the combined results of two
sets of experiments.
somes were statistically comparable with the steri-
 .cally stabilized liposomes P)0.05 .
Comparison with other PE derivatives in Table 1
demonstrates that this effect of the dicarboxylic acid
derivative was clearly dependent on its structure. For
instance, the N-succinyl-DPPE derivative was nearly
as effective in circulation time enhancement as the
N-glutaryl derivative, but the N-butyryl- and N-
valeryl derivatives were significantly less effective
 .P-0.01 . DSPCrN-tartaryl-DPPE does not fit this
hypothesis, but also differs in other characteristics,
Table 1
Comparisons of in vivo circulation lifetimes for different DSPC LUV formulations
bClassification Formulation Normalized AUC
a  .Controls DSPC 0.04"0.02 4
a  .DSPCrchol, 2:1 0.34"0.04 5
 .DSPCrPEG-DSPE, 9:1 1.16"0.05 4
 .  .N- v-carboxy acylamido-PEs DSPCrN-glutaryl-DPPE, 9:1 1.00"0.15 15
 .DSPCrN-succinyl-DPPE, 9:1 0.81"0.13 4
a  .DSPCrN-tartaryl-DPPE, 9:1 0.35"0.09 6
a  .N-acylamido-PEs DSPCrN-butyryl-DPPE, 9:1 0.49"0.03 3
a  .DSPCrN-valeryl-DPPE, 9:1 0.52"0.05 3
a  .Statistically significant difference in AUC from DSPCrN-glutaryl-DPPE 9:1 LUV formulation, P-0.01.
b Area under the curve"standard deviation, calculated as described in Section 2. The number of measurements is indicated in
parentheses.
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Fig. 4. Liposome-induced in vitro complement binding. Serum
dilution factor is defined as a fraction, i.e. a 1:100 dilution of
serum is equal to 0.01. Complement depletion determined as
.described in Section 2 is indicated by a shift of the hemolysis
 .curve to the right as described in Section 2 . Complement-in-
duced hemolysis curves are shown for serum that was incubated
 .  .  .with buffer -B- , DSPCrcholrDSPG 2:4:4 LUVs -v- ,
 .  . DSPCrN-glutaryl-DPPE 9:1 LUVs -l- or DSPC LUVs -’-
..
such as its capability for hydrogen bonding and ap-
 .parent pK see Section 2 . Modification of the DSPC
chain packing by the addition of cholesterol in
 .DSPCrchol 2:1 liposomes also does not enhance
the circulation lifetime as effectively as N-glutaryl-
DPPE, the most efficacious derivative.
3.2. Effect of N-glutaryl-DPPE on in ˝itro comple-
ment depletion by liposomes
The possibility that N-glutaryl-DPPE enhances the
circulation time by reducing complement opsoniza-
tion of DSPC liposomes was next investigated in
vitro using an antibody-activated sheep red blood cell
Fig. 5. Liposome size dependence of circulation lifetime. The
 .AUCs of DSPCrN-glutaryl-DPPE 9:1 liposome formulations
with various size distributions are plotted versus the surface
area-weighted average diameter of the formulations. The AUCs
were calculated as described in Section 2. Each AUC was
 .normalized to the AUC of the DSPCrN-glutaryl-DPPE 9:1
LUVs extruded through 200 nm pores. The surface area-weighted
diameter and distribution half-width, along with the number of
experiments for each liposome formulation were the following:
 .  .SUVs: 32"11 nm 3 ; 50 nm pore: 52"16 nm 5 ; 80 nm pore:
 .  .69"17 nm 6 ; 200 nm pore: 167"65 nm 15 ; 400 nm pore:
 .  .252"138 nm 4 ; 600 nm pore: 298"150 nm 3 ; 800 nm pore:
 .  .357"254 nm 5 and IFVs: 1040"580 nm 2 . The weighted
averages typically varied by no more than "10% over multiple
measurements.
 .hemolysis assay see Section 2 . In these complement
binding assays, the liposomal test samples were al-
ways compared to buffer alone, as a negative control,
and the liposomal composition of DSPCrcholrDSPG
 .2:4:4 , as a positive control. The latter is similar to
compositions previously shown to strongly activate
w xcomplement 10 . Fig. 4 shows typical hemolysis
curves for rat serum that was pre-incubated with
several DSPC-containing liposome preparations.
Table 2
Effects of N-glutaryl-DPPE and PEG-DSPE on circulation lifetime of a liposome composition that fixes complement
a b .Liposome formulation AUC relative % CH50 decrease
c  .  .DSPCrcholrDSPG, 2:4:4 0.05"0.01 4 68.3"5.0 7
c  .  .DSPCrcholrDSPGrN-glutaryl-DPPE, 1:4:4:1 0.02"0.0007 4 88.9"1.9 3
 .  .DSPCrcholrDSPGrPEG-DSPE, 1:4:4:1 0.90"0.13 4 19.1"4.8 3
a  .Area under the curve, calculated as described in Section 2 relative to N-glutaryl-DPPErDSPC 9:1 .
b CH50 defined in Section 2 and the caption to Fig. 4. The percentage CH50 decrease is relative to the CH50 of buffer alone, which was
 .taken as 100% i.e. 0% decrease . A decrease of CH50 represents more complement binding by the liposomes. The number of
experiments is given in parentheses.
c  .Statistically significant difference in AUC from DSPCrN-glutaryl-DPPE 9:1 LUV formulation, P-0.01.
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While the positive control, DSPCrcholrDSPG
 . 2:4:4 , produced a significant shift to the right CH50
.decrease relative to the buffer control, indicating
depletion of complement from the serum, neither the
 .DSPC nor the DSPCrN-glutaryl-DPPE 9:1 formu-
lations appeared to bind significant amounts of com-
plement from the serum. The same result was ob-
 .served in rat plasma data not shown . Therefore,
N-glutaryl-DPPE did not appear to enhance the circu-
lation time of DSPC by inhibiting complement op-
sonization.
A related question is whether N-glutaryl-DPPE
could reduce opsonization andror increase the circu-
lation time of formulations that do bind complement.
Therefore, we utilized our positive complement bind-
 .ing control, DSPCrcholrDSPG 2:4:4 , and replaced
some of the DSPC with N-glutaryl-DPPE to give
 .DSPCrcholrDSPGrN-glutaryl-DPPE 1:4:4:1 . This
 .  . Fig. 6. Aggregation level of DSPC LUV formulations. The aggregation level of DSPC b and d and DSPCrN-glutaryl-DPPE 9:1 a and
.  .  .c in rat serum a and b or plasma c and d are shown. The lipid concentration in all samples was adjusted to approximately 2 mM, the
concentration expected for complete dilution of the injected dose into the blood volume of a rat. The plasma sample contained a
background of particles, largely consisting of platelets. The photomicrographs were taken using 20= objective phase contrast imaging
optics. The bar in each photomicrograph corresponds to 20 mm.
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composition bound even more complement than the
positive control and the clearance from plasma was
 .also even faster Table 2 . If the sterically stabilizing
phospholipid, PEG-DSPE, was used to replace DSPC
instead of N-glutaryl-DPPE, the circulation time was
greatly increased, while opsonization was greatly de-
 .creased Table 2 . These data confirm the fact that,
unlike PEG-phospholipids, N-glutaryl-DPPE does not
inhibit complement opsonization and, in fact, it can
even enhance it under some circumstances.
3.3. Size dependence of DSPCrN-glutaryl-DPPE
LUV circulation lifetime
Having shown the absence of an opsonization
effect, it was of interest to determine if N- v-
.carboxy acylamido-PEs could influence other factors
that affect the circulation lifetime. Since the circula-
tion lifetimes of other liposomes are dependent on
 .size see Section 4 , it was of interest to first confirm
 .this dependency for DSPCrN-glutaryl-DPPE 9:1
LUVs in our system. In Fig. 5, data are shown that
clearly demonstrate this size-dependence under con-
ditions where dynamic light scattering, microscopy
and turbidity revealed that there was no significant
level of liposomal aggregation. The size was optimal
for circulation in the 100 to 200 nm diameter range.
3.4. N-glutaryl-DPPE reduction of liposome aggrega-
tion
The pure DSPC liposomes used in these experi-
ments were shown initially by dynamic light scatter-
ing to have the same optimal 100 nm size as N-
glutaryl-DPPE-containing liposomes data not
.shown . However, after incubation at room tempera-
ture, several observations indicated that limited ag-
gregation had occurred. Measurements by dynamic
light scattering indicated that these aggregates were
beyond the size range where the method is applicable
 .)1 mm, data not shown . Although aggregates
visible to the eye did not form, phase contrast pho-
tomicrographs at room temperature demonstrated
substantial aggregation in either serum or plasma, as
 .shown in Fig. 6. DSPC liposomes Fig. 6b and d
were highly aggregated while DSPCrN-glutaryl-
 .DPPE liposomes were not aggregated Fig. 6a and c .
The majority of the observed aggregates were at least
Fig. 7. Correlation between LUV aggregation level and in vivo
circulation lifetime. All turbidity measurements were made at
 .room temperature see Section 2 . The turbidity value is defined
for a 1-mm path-length cuvette as the OD at 450 nm per mM
lipid=1000. The individual formulations shown in the figure are
 .labeled as follows: A DSPCrcholrDSPGrPEG-DSPE
 .  .  .  .1:4:4:1 ; B DSPCrPEG-DSPE 9:1 ; C DSPCrN-succinyl-
 .  .  .  .DPPE 9:1 ; D DSPCr N-glutaryl-DPPE 9:1 ; E
 .  .D SPCrcholrD SPG r N -glutaryl-D PPE 1:4:4:1 ; F
 .  .  .DSPCrcholrDSPG 2:4:4 ; G DSPCrN-valeryl-DPPE 9:1 ;
 .  .  .H DSPCrN-butyryl-DPPE 9:1 ; I DSPCrN-tartaryl-DPPE
 .  .  .  . ).9:1 ; J DSPCrchol 2:1 and K DSPC. An asterisk
indicates that liposome aggregates were observed for the LUV
formulation at room temperature using 40= oil immersion No-
marski microscopy.
10 mm in diameter. DSPC liposomes containing N-
valeryl-DPPE, N-butyryl-DPPE or N-tartaryl-DPPE
also showed aggregates of smaller average size than
 .for pure DSPC not shown . In contrast, similarly
prepared DSPCrN-succinyl-DPPE or DSPCrPEG-
DSPE LUVs at the same concentration had no ten-
dency to form any microscopically visible aggregates
 .at room temperature data not shown . When DSPC
liposomes and N-glutaryl-DPPErDSPC liposomes
were compared in buffer at the expected dilution after
injection into rats, it was also clear that only the
 .DSPC liposomes were aggregated data not shown .
The relative turbidity of each LUV formulation
was consistent with microscopic observations of ag-
gregation. These measurements give an indication of
the relative proportion of large liposomal aggregates
in each of the formulations, although direct calcula-
tion of the size distributions are not possible from
w xturbidity measurements 48 . When turbidity was
plotted versus circulation lifetime in Fig. 7, it was
clear that there was a strong correlation between the
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Fig. 8. In vivo circulation lifetime enhancement requires both low levels of liposomal aggregation and complement activation.
Normalized AUC, aggregation and complement activation were determined as described in previous figure captions and in Section 2.
two parameters for those formulations that do not
opsonize well. For opsonized formulations the two
.points in the lower left-hand corner of the figure ,
circulation lifetimes were short, despite the lack of
any tendency to aggregate. Therefore, liposomal ten-
dency for aggregation and complement opsonization
appear to be two separate and important determinants
of the circulation lifetime of optimally sized DSPC
LUVs. Fig. 8 demonstrates that only liposomes that
were both poorly opsonized and disaggregated had
long circulation lifetimes.
4. Discussion
The biphasic behavior of liposome plasma clear-
ance profiles and the effect of liposome size on in
vivo circulation lifetime have been noted previously
w x20,49,50 , but the mechanism of size-dependent
clearance remains unknown. Furthermore, the rela-
tively large effect that a tendency to aggregate can
have on in vivo liposome circulation lifetime has not
been well recognized. Non-aggregated DSPCrN-
glutaryl-DPPE LUVs clearly have an optimal particle
diameter for long circulation in the range of 100 to
.200 nm that rapidly drops off over approximately
300 nm, similar to DSPC liposomes containing
w xPEG-DSPE 51 . Therefore, the circulation lifetime of
these liposomes is highly dependent on relatively
small changes in average particle diameter, which
could result from even relatively low levels of liposo-
mal aggregation into small clusters of even a few
vesicles. It is clear that the observed tendency to
aggregate in buffer, serum and plasma is sufficient to
strongly influence the circulation lifetime. Therefore,
rapid clearance of these liposomes appears to be
mediated by a size-dependent mechanism that is not
necessarily related to previously observed comple-
w xment-mediated clearance 52–56 , although a poten-
tial role for other opsonins besides those in the
complement cascade has not yet been investigated.
Small effects of liposomal size on complement op-
sonization of fluid-phase liposomes have been re-
w xported 10,59 , but opposite size dependence for in
vitro uptake by cultured macrophages versus in vivo
clearance have also been noted, suggesting a separate
macrophage-independent mechanism of size-depen-
w xdent clearance in vivo 50 .
This size-dependent mechanism of rapid clearance
may be associated with a shift in biodistribution.
w x w xStudies by Liu et al. 57 and Litzinger et al. 58
have shown that small-diameter long-circulating
LUVs containing either GM or PEG-linked phos-1
pholipids accumulate primarily in the liver. However,
liposome accumulation shifted to spleen, when the
average diameter of the liposome formulation was
increased, possibly indicating a filtering mechanism.
It has also been shown that very large particles can
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become trapped in the capillary beds of the lungs,
w xe.g. 66 . Similar size-dependent biodistribution shifts
might be occurring for liposomal aggregates and
might be the basis for the apparently biphasic DSPC
LUV clearance kinetics.
Many liposomal formulations only weakly bind
complement components because opsonization occurs
w xonly when certain physical criteria are met 10,60,61 .
w xDevine et al. 10 clearly demonstrated that the den-
sity of surface charge is a crucial factor in promoting
complement fixation. A relatively highly charged sur-
face was necessary to fix complement, and this was
w xgreatly enhanced by the presence of cholesterol 10 .
Pure DSPC liposomes do not meet these comple-
ment-binding criteria, but the absence of any net
charge and relatively low surface hydration may al-
low attractive van der Waals forces to dominate
liposome–liposome interactions such that aggregation
w xbecomes a factor for large DSPC vesicles 62,63 .
The negative surface charge conferred by the divalent
 .N- v-carboxy acylamido-PEs would be expected to
create an electrostatic repulsive force that disaggre-
gates these liposomes. Some negatively charged
derivatives disaggregated the liposomes better than
others, indicating the importance of the divalency,
effective pK values and structural features, such as
the possible extension of the N-glutaryl carboxyl
group a relatively large distance away from the mem-
brane surface.
These results correspond in many respects to those
w x of Park et al. 37 who showed that some N- v-
.carboxy acylamido-PEs improved the circulation life-
time of fluid phase egg phosphatidylcholine–chol
 .EPC–chol LUVs. Structural dependence was also
observed, although with some differences, from those
found in the DSPC liposomes. The mechanism of
clearance of the EPC–chol liposomes was not deter-
mined, but it was suggested that lipid structure-
specific dysopsonin binding may inhibit clearance of
the derivatized liposomes. The possibility of limited
liposomal aggregation was not considered in this
study, but we have observed partial aggregation of
identical EPC–chol liposomes by turbidity and mi-
croscopic observation under conditions similar to
 .those reported data not shown . Inclusion of 6 mol.%
N-glutaryl-DOPE eliminated the aggregation, sug-
gesting that inhibition of such aggregation may ac-
count, at least in part, for the ability of N- v-
.carboxy acylamido-PEs to enhance the circulation
lifetimes of these fluid phase liposomes.
One obvious correlate of the results presented in
this manuscript is that large sterically stabilizing
polymer additives are not necessary in all cases to
generate liposomes with long circulation lifetimes.
The average circulation half-time for 100 nm
DSPCrN-glutaryl-DPPE liposomes was statistically
 .indistinguishable P)0.05 from the circulation
half-time of DSPCrPEG-DSPE liposomes in the ex-
periments presented here. It is difficult to make direct
quantitative comparisons between our results and pre-
viously published circulation half-times for other li-
posomes containing GM , hydrogenated PI, or one of1
several hydrophilic polymer-linked phospholipids
w x11–28 because of differences in animal systems or
other conditions. However, it is clear that the reduc-
tion of aggregation-related uptake by the use of N-
glutaryl-DPPE at only 10 mol.% generates a new
class of long-circulating liposomes.
Depending on the desired agent and mechanism of
delivery, gel-phase long-circulating liposomes may
be particularly desirable. Rigid gel-phase bilayers are
probably more stable in vivo because they appear to
be less susceptible than more fluid liquid-crystalline
bilayers to penetration by lipoproteins and lipid loss
w xto serum components by exchange 52,53,64 , al-
though incorporation of cholesterol can increase sta-
w xbility 65 . Furthermore, PEG-linked phospholipids
do not protect fluid-phase bilayers from some serum
components that induce leakage and lipid transbilayer
w xdiffusion 67 . PEG-phospholipids may also block
desired liposome-cell surface contacts that are neces-
sary for drug delivery mediated by the binding of
liposomal ligands, although coupling to the outer
w xPEG surface may help in some cases 68 . It is
possible that gel-phase long-circulating liposomes
 .containing N- v-carboxy acylamido-DPPEs will
complement sterically stabilized liposomes and over-
come some of these problems.
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